Tula region will buy an antitumor drug for 22 million rubles

Tula region is preparing the purchase of the drug nintedanib in capsules. For these purposes, the Ministry of Health will spend more than 22 million rubles.

In total, 10.8 thousand units of the drug in capsules will be purchased. This drug is intended for the treatment of idiopathic pulmonary fibrosis, non-small cell lung cancer, as well as other chronic fibrosing interstitial lung diseases. Nintedanib is a tyrosine kinase inhibitor that blocks growth factor receptors, slowing fibrous tissue remodeling and tumor vessel growth.

The drug will be distributed in shipment order and delivered in full – 100% of deliveries are planned for the period from 14 to 23 December 2026.

According to the specification, the drug should be delivered in whole packages - without violating the primary and secondary (consumer) packaging. The residual shelf life at the time of delivery should be at least 8 months (with a total shelf life of 12 months) or at least 12 months (with a shelf life of more than 12 months).

All loading and unloading works, including work with the use of lifting equipment, are performed by the supplier. Thermolabilic drugs should be transported in compliance with the so-called cold chain in accordance with sanitary and epidemiological requirements.